Celldex Therapeutics, Inc. (CLDX) Stock
Key stats
- Market cap
- $2.37B
- Price / Earnings ratio
- -7.8x
- EPS (TTM)
- -$4.31
- Volume
- Loading
- 52-week high
- $45.14
- 52-week low
- $22.10
Source: third-party data provider, as of November 13, 2026
Compare with CLDX
Recent news

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
CLDX

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
CLDX

4 Biotech Stocks With Key Clinical Readouts Expected This Fall
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
CLDX

Celldex's skin disease drug meets goals in two late-stage trials
Celldex's skin disease drug meets goals in two late-stage trials
CLDX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.42
- MACD 12/26/9
- -0.46
- EMA 9 of MACD
- -0.81
- MACD histogram
- 0.36
- SMA 50
- $32.41
- Price below SMA 50
- EMA 50
- $31.92
- Price below EMA 50
- SMA 200
- $32.80
- Price below SMA 200
- EMA 200
- $31.59
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
CLDX

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
CLDX

4 Biotech Stocks With Key Clinical Readouts Expected This Fall
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
CLDX

Celldex's skin disease drug meets goals in two late-stage trials
Celldex's skin disease drug meets goals in two late-stage trials
CLDX

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
CLDX

Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
CLDX

Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
CLDX

CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?
CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?
CLDX

Celldex to stop skin disease study after trial setback
Celldex to stop skin disease study after trial setback
CLDX

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
CLDX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Celldex Therapeutics, Inc.
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Anthony S. Marucci M.B.A. | Founder, President, CEO & Director | 1962 |
| Mr. Sam Martin CPA | Senior VP, CFO, Secretary & Treasurer | 1971 |
| Dr. Tibor Keler Ph.D. | Founder, Chief Scientific Officer & Executive VP | 1959 |
| Ms. Elizabeth Crowley | Chief Product Development Officer & Senior VP | 1972 |
| Dr. Margo Heath-Chiozzi M.D. | Senior Vice President of Regulatory Affairs | 1957 |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1945 |
| Ms. Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration | 1975 |
| Mr. Freddy A. Jimenez Esq. | Senior VP & General Counsel | 1969 |
| Dr. Ronald A. Pepin Ph.D. | Chief Business Officer & Senior VP | 1956 |
| Dr. Diane C. Young M.D. | Senior VP & Chief Medical Officer | 1957 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 48.42
- MACD 12/26/9
- -0.46
- EMA 9 of MACD
- -0.81
- MACD histogram
- 0.36
- SMA 50
- $32.41
- Price below SMA 50
- EMA 50
- $31.92
- Price below EMA 50
- SMA 200
- $32.80
- Price below SMA 200
- EMA 200
- $31.59
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $61.00
- Average
- $70.60
- High
- $88.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.4 | +7.1 | ||||||||||
| 2022 | -20.9 | -5.2 | +7.9 | -10.4 | -24.3 | +18.5 | +35.3 | +2.8 | -8.3 | +26.5 | +4.9 | +21.6 |
| 2023 | +1.5 | -2.1 | -22.5 | -12.2 | +1.4 | +5.6 | +1.8 | -19.7 | -4.5 | -14.1 | +28.2 | +23.9 |
| 2024 | -12.8 | +35.4 | -19.1 | -10.1 | -15.4 | +10.6 | -2.3 | +10.1 | -18.1 | -19.6 | +6.9 | -7.2 |
| 2025 | -5.0 | -13.0 | -6.2 | +23.6 | -4.5 | +1.9 | +3.6 | -0.5 | +17.3 | +5.7 | +9.2 | +4.8 |
| 2026 | -8.9 | +22.0 | +5.7 | +5.2 | -2.7 | +23.5 | +3.5 | +5.1 | -17.4 | -6.5 | +3.8 |



